tbuckley/cabot-search huggingface dataset:
POS1561 MIXED CONNECTIVE TISSUE DISEASE AND COURSE OF PREGNANCY - RESULTS FROM THE NATIONWIDE PREGNANCY REGISTER REVNATUS
Authors: H. S. Koksvik, B. Jakobsen, H. Bjørngaard, T. T. Pedersen, M. Wallenius
Journal: Annals of the Rheumatic Diseases (2023)

<h3>Background</h3> Mixed connective tissue disease (MCTD) is a complex and multisystemic disorder of unknown etiology. MCTD is classified by the presence of antibodies to U1-RNP and associated with clinical symptoms like "puffy hands", Raynaud's phenomenon, arthritis, synovitis, sclerodactyly/acrosclerosis and/or myositis. It is commonly diagnosed in women of reproductive age. Pregnancy outcomes are reported in previous studies with discrepancies in the rate of pregnancy-related complications [1]. <h3>Objectives</h3> To describe the course of pregnancy in patients with MCTD. <h3>Methods</h3> We prospectively collected data on pregnancy outcome in women with MCTD through the nationwide Norwegian quality registry on pregnancy and rheumatic diseases (RevNatus) from 2016-2022. All women were diagnosed with ICD-10 code M35.1. 48 pregnancies in 38 women were recorded. One woman had twin birth. <h3>Results</h3> Mean maternal age at first trimester was 31 years, (SD= 4,3). Mean disease duration was seven years (SD= 4,2). One patient had BMI &gt; 30 at first trimester, and one patient had diabetes. Median gestational age at delivery was 37 weeks (range 25-41). No stillbirths were recorded. Two pregnancies were not planned. 69% of the women were in clinical remission at inclusion. <h3>Conclusion</h3> Most patients with MCTD in this cohort had a favourable course and outcome of pregnancy and most pregnancies were planned. Four patients were diagnosed with HELLP syndrome and we observed an increased rate of preeclampsia compared to the frequency reported in the Norwegian birth registry (NFR) (17% vs 4%) and we found lower mean birth weight in gram compared to NFR (2995 vs 3480). Hydroxykloroquin was used by a majority (&gt;70%), of the women throughout pregnancy and might have contributed to the favorable course and outcome. Analysis on the association to specific risk factors predicting adverse pregnancy outcomes should be done in the future. <h3>Reference</h3> [1]Radin M, Schreiber K, Cuadrado MJ, Cecchi I, Andreoli L, Franceschini F, et al. Pregnancy outcomes in mixed connective tissue disease: a multicentre study. Rheumatol Oxf Engl 2019;58:2000–8 <h3>Acknowledgements:</h3> NIL. <h3>Disclosure of Interests</h3> None Declared.
AB0573 REASONS FOR BREASTFEEDING AVOIDANCE: A MULTICENTER INSIGHT IN MOTHERS WITH SYSTEMIC LUPUS ERYTHEMATOSUS
Authors: S. G. Foddai, M. Radin, K. Schreiber, I. Cecchi, F. Signorelli, G. De Jesùs, K. Aso, M. Kono, M. L. Urban, B. Bacco, S. Gallo Cassarino, L. Lo Sardo, M. Arbrile, A. Barinotti, I. Gómez-García, M. I. Quaglia, Y. Tissera, F. Gervasoniuniversity of Turin, M. Á. Aguirre-Zamorano, P. Alba, C. Benedetto, T. Atsumi, O. Amengual, G. Emmi, D. Andrade, L. Marozio, D. Roccatello, S. Sciascia
Journal: Annals of the Rheumatic Diseases (2023)

<h3>Background</h3> Even though the health benefits of breast milk are well established, only a small number of research have looked at breastfeeding in people with systemic lupus erythematosus, with mixed findings. In a previous multicenter cohort investigating 119 SLE pregnancies, one-third of patients did not breastfeed after giving birth. <h3>Objectives</h3> To study the causes of breastfeeding avoidance with the purpose to increase the standard of care of SLE women. <h3>Methods</h3> A priori questionnaire was created and administered to patients by structured-phone interview (Table 1). Pregnancy outcomes were retrospectively collected. <h3>Results</h3> A total of 22 questionnaires of women who did not breastfeed after first birth were collected. Twelve out of 22 (54.5%) patients experienced a disease flare in the 24 months following the delivery. Healthcare professional advice (36.4%) was the most frequently reported reason for not breastfeeding, followed by the mothers' fear that medications (drugs) taken during pregnancy (22.7%) and/or the circulating autoantibodies (4.5%) could be passed onto the baby and therefore harm the new-born. In 10 (45%) cases, breastfeeding was not possible because of mother's or neonatal clinical complications. One woman did not breastfeed for a personal choice. After giving birth, only nine out of 22 patients (40.9%) declared to have had adequate breastfeeding training, with 58% of women reporting a breastfeeding-training time of less than 5 minutes in those without an adequate counselling. Most patients (21 out of 22, 95.5%) stated that they would have breastfed their child if they could. <h3>Conclusion</h3> Breastfeeding avoidance in women with SLE is frequently the result of a confluence of individual preference, clinical advice, and the societal context. An implementation of patients-to-patients network, together with an update of health practitioners, may help to increase the frequency of breastfeeding in women with SLE and subsequently improve patients' care. In Figure 1 implementation points suggested by patients. <h3>References</h3> [1]Radin et al. Disease activity at conception predicts flare up to 2 years after birth: A multicentre long term follow-up study. <h3>Acknowledgements:</h3> NIL. <h3>Disclosure of Interests</h3> None Declared.
POS1092 PHYSICAL ACTIVITY AND SEDENTARY BEHAVIOR IN PATIENT WITH CHRONIC INFLAMMATORY RHEUMATIC DISEASES: A CASE CONTROL STUDY
Authors: A. Adnine, F. Z. Taik, N. Takhrifa, N. Soba, F. Z. Aharrane, M. Fourtassi, F. E. Abourazzak
Journal: Annals of the Rheumatic Diseases (2023)

<h3>Background</h3> Engaging in regular physical activity (PA) is important in maintaining health and increasing the overall quality of life of patient living with chronic inflammatory rheumatic diseases (CIRD). Its is assumed that patients with CIRD reports low levels of physical activity. In the era of evidence-based medicine few studies compare PA levels and its predictors between patient with CIRD and healthy control. <h3>Objectives</h3> we aim to investigate PA levels of patients with CIRD, to examine predictors of PA and furthermore compare findings to healthy control. <h3>Methods</h3> A cross-sectional study was performed among patients with CIRD Aged between 18 and 65 years old who visited the outpatient clinic between April 2022 and October 2022. The diagnosis of spondyloarthritis was based on ASAS criteria and the diagnosis of rheumatoid arthritis was based on ACR/EULAR 2010 criteria. Healthy controls were recruited in a specialized consultation. Socio-demographic findings were collected. Patients were assessed for pain and disease activity using visual analogic scale (VAS), DAS28 CRP and ASDAS CRP. Physical activity levels were assessed using the international physical activity questionnaire (IPAQ-SF). Furthermore, all participants underwent screening for anxiety and depressive disorders using Patient health questionnaire (PHQ-9) and General anxiety disorder (GAD-7) respectively. <h3>Results</h3> The final study simple was made up of 172 patients (92 RA, 65 SpA and 15 Undifferentiated CIRD) and 159 healthy controls. <h3>Conclusion</h3> Our study shows that patients with CIRD reports significantly low levels of PA and high level of SB compare to healthy controls. The unexpected finding in our study is that low levels of PA in patients with CRDI were not associated with disease activity nor disease duration. Depressive disorders are an important predictor of physical inactivity and sedentary behavior regardless of the presence of CRID. Depressive disorders are common among patients with CRID. Screening for depression and treating in time is essential to help overcome sedentary behavior in our patient and community. <h3>REFERENCES:</h3> NIL. <h3>Acknowledgements:</h3> NIL. <h3>Disclosure of Interests</h3> None Declared.
AB0334 PREVALENCE AND ASSOCIATED FACTORS OF MULTIMORBIDITY IN PATIENTS WITH STABLISHED RHEUMATOID ARTHRITIS. DATA FROM THE CRHREAR REGISTRY
Authors: M. Rojas-Giménez, S. Dans-Caballero, M. Parra-Moreno, M. Á. Puche Larrubia, M. Rico-Muñoz, R. Ortega Castro, C. López-Medina, J. Calvo Gutierrez, M. L. Ladehesa Pineda, A. Escudero Contreras
Journal: Annals of the Rheumatic Diseases (2023)

<h3>Background</h3> Patients with Rheumatoid Arthritis have an increased risk of developing comorbidities that contribute to increased worsened quality, disability and mortality. Knowledge of comorbidity is important when attempting to identify the conditions most associated with the greatest morbidity and mortality. However, comorbidities in RA are often underrecognized despite their impact on disease activity and treatment outcomes. <h3>Objectives</h3> To evaluate the prevalence of multimorbidity in a cohort of patients with stablished Rheumatoid Arthritis (RA) and the factors associated with such condition. <h3>Methods</h3> Cross-sectional observational study of a cohort of patients with RA according to the ACR/EULAR 2010 criteria of the CRhreAR registry of the Reina Sofia University Hospital of Córdoba. Multimorbidity was defined, according to the WHO, as the presence of two or more chronic diseases, in addition to RA. Comorbidities included in the Charlson index were collected, in addition to others such as arterial hypertension (HT), dyslipidemia (DL), diabetes mellitus, depression, osteoporosis, interstitial lung disease, and thyroid pathology. Other sociodemographic and disease-related variables were collected. Statistical analysis: descriptive, bivariate analysis and multivariate logistic regression to evaluate variables independently associated with multimorbidity. <h3>Results</h3> A total of 233 patients were included (mean age 63.6 (13.4) years and 70.4% women). More than 70% were ACPA and RF positive. 99.1% had used any csDMARD and 42.1% any bDMARD. The disease duration was 13.7 years (11.6). 192 patients had at least one comorbidity. 151 (64.8%) had multimorbidity, and the mean age-adjusted Charlson index was 2.9 (2.4). The most frequent morbidity was HT (45.1%) and DL (47.6%), followed by osteoporosis (27.5%) and ILD (16.7%). The most frequent comorbidities included in the Charlson index were cardiovascular disease (14.2%) and cancer (11.2%). Table 1 shows the differences between patients with and without multimorbidity. The multivariate analysis showed that the diagnosis delay of RA [OR 1.31; IC95 (1.1-1.7)], age [OR: 1.2; IC95 (1.1-1.23)] and the number of bDMARDs used since the diagnosis [OR: 2.7; IC95 (1.7-4.3)] were independently associated with multimorbidity, adjusted by sex. <h3>Conclusion</h3> These results suggest that the presence of multimorbidity in stablished RA was high (64.8%). The most frequent comorbidities were arterial hypertension, dyslipidemia, interstitial lung disease, and osteoporosis. The diagnosis delay of RA, age and the number of bDMARDs used were independently associated with the presence of multimorbidity. <h3>REFERENCES:</h3> NIL. <h3>Acknowledgements:</h3> NIL. <h3>Disclosure of Interests</h3> None Declared.
POS0996-HPR THE PREVALENCE OF PULMONARY ARTERIAL HYPERTENSION IN PATIENTS WITH MIXED CONNECTIVE TISSUE DISEASE: A SYSTEMATIC REVIEW AND META-ANALYSIS
Authors: A. Al-Bakri, R. Hozayen, Z. Mustafa, I. E. Lundberg, H. Jahrami
Journal: Annals of the Rheumatic Diseases (2023)

<h3>Background</h3> The prevalence and outcome of mixed connective tissue disease-associated pulmonary arterial hypertension (MCTD-PAH) has not been well understood. <h3>Objectives</h3> Our aim was to review the current knowledge on the prevalence, severity, and mortality of MCTD-PAH. We also aimed to examine the trend of the prevalence of MCTD-PAH over the years. <h3>Methods</h3> PubMed/Medline, Embase, Scopus and Web of Science electronic databases were searched for the published randomized controlled clinical trials (RCTs) and observational/original studies on PAH in patients with MCTD from January 1972 – December 2020. <h3>Results</h3> The results were pooled using random-effects meta-analysis based on the DerSimonian and Laird method. A total of 983 patients from eight studies were included in the meta-analysis (K=8, N=983). Pooled prevalence of PAH in MCTD patients was 12.53% [95% CI 8.30%-18.48%] with significant level statistical heterogeneity tau2=0.30, tau=0.55, I2 83.3%, H=2.13 Q(df,7) =31.90, P=0.001. There was no association between PAH and female gender or age. The percentage of deaths in MCTD patients due to PAH varied and reached up to 81.8%. <h3>Conclusion</h3> This is the first systematic review and meta-analysis investigating the prevalence of PAH in patients with MCTD and it revealed an overall prevalence of PAH in patients with MCTD of 12.53%. Our results showed trends of reduced prevalence of MCTD-PAH over the years, reconfirmed the lower prevalence rate in the recent studies, but revealed increased mortality rate. We also determined the low impact of the age, gender, and interstitial lung disease on MCTD-PA.H. <h3>REFERENCES:</h3> NIL. <h3>Acknowledgements:</h3> NIL. <h3>Disclosure of Interests</h3> None Declared.
AB0079 THEAFLAVIN ALLEVIATES COLLAGEN-INDUCED ARTHRITIS IN MICE BY DECREASING REACTIVE OXYGEN SPECIES AND PRO-INFLAMMATORY CYTOKINES
Authors: W. N. Huang, C. C. Lin
Journal: Annals of the Rheumatic Diseases (2023)

<h3>Background</h3> An autoimmune disease that causes inflammation and bone and cartilage deterioration is rheumatoid arthritis (RA). In the pathogenesis of RA, oxidative stress and pro-inflammatory cytokines are important factors. The main polyphenol in black tea, theaflavins (TFs), has been used medically to treat a variety of inflammatory illnesses by reducing inflammation and reactive oxygen species (ROS) <h3>Objectives</h3> The medications available to treat RA have a variety of side effects. The current study was designed to assess the anti-arthritic properties of theaflavin in a mouse collagen-induced arthritis model. <h3>Methods</h3> In order to induce arthritis in DBA/1 mice, type II collagen was administered intradermally. From days 21 through days 42, different doses of theaflavin (50 and 100 mg/kg/day) were orally administered. To determine the effect of theaflavin on collagen-induced arthritis, histological analyses were conducted. In addition, the generation of reactive oxygen species (ROS), nitric oxide, and the activities of enzymatic antioxidants (superoxide dismutase, glutathione peroxidase, catalase, and glutathione reductase) in the joint homogenate of mice were examined. The levels of TNF-, IL-6, and IL-1β were also measured by ELISA to detect inflammation. <h3>Results</h3> Our results showed anti-oxidant and anti-inflammatory effects of theaflavin in arthritic mice. Histopathological studies corroborated the anti-arthritic properties of theaflavin. The compound was found to be effective in lowering ROS and nitric oxide levels while increasing enzymatic antioxidant levels. Theaflavin therapy also reduced TNF-, IL-6, and IL-1β levels. <h3>Conclusion</h3> In mice with arthritis, theaflavin was successful in reducing inflammation and oxidative stress. These results suggest that theaflavin may be used in conjunction with other treatments to manage RA. <h3>REFERENCES:</h3> NIL. <h3>Acknowledgements:</h3> NIL. <h3>Disclosure of Interests</h3> None Declared.
AB0372 THE IMPACT OF BODY MASS INDEX ON BONE MINERAL DENSITY IN RHEUMATOID ARTHRITIS
Authors: Z. Baba, A. Rafi, F. E. Chekkouri, A. Mougui, I. El Bouchti
Journal: Annals of the Rheumatic Diseases (2023)

<h3>Background</h3> It has long been thought that a higher body mass index is protective against osteoporosis. However, recent studies showed an increase in fracture risk in obese individuals. <h3>Objectives</h3> To study the impact of body mass index (BMI) on bone mineral density (BMD) during rheumatoid arthritis (RA). <h3>Methods</h3> Retrospective study including 260 RA patients meeting the ACR/EULAR 2010 criteria. We collected demographic, clinical, biological, and bone densitometric data from patients. <h3>Results</h3> The mean age was 49.91 ± 12.97 years. The sex ratio F/H was 6.6. The mean DAS28-VS was 5.32 ± 1.35. According to the DAS28-VS, 60.7% of the patients were high activity. The mean BMI was 26.26 ± 4.83 Kg/m². 21.9% of patients were obese, 31.5% were overweight and 2.3% were underweight. The mean BMD was 0.856 ± 0.200 g/cm² at the femoral neck and 0.950 ± 0.218 g/cm² at the lumbar spine. The mean T-SCORE was -1.41 ± 1.48 at the femoral neck and -1.90 ± 1.58 at the lumbar spine. Osteoporosis at one of the two sites was found in 38.4% of patients. Eleven patients (4.8%) had a severe fracture and 6 patients (2.6%) a non-severe fracture. A negative correlation was found between BMI and the presence of osteoporosis at one of the two sites (r=-0.138; p=0.04). BMI was also correlated with T-Score and BMD at the lumbar spine (r=0.196; p=0.007 and r=0.278; p=0.001 respectively). No correlation was found between BMI and T-Score and BMD at the femoral neck level as well as fracture occurrence. <h3>Conclusion</h3> In our study, BMI correlated with BMD and T-SCORE at the lumbar spine, and negatively correlated with the presence of osteoporosis. <h3>Reference</h3> [1] Gkastaris K, Goulis DG, Potoupnis M, Anastasilakis AD, Kapetanos G. Obesity, osteoporosis and bone metabolism. J Musculoskelet Neuronal Interact. 2020 Sep 1;20(3):372-81. <h3>Acknowledgements:</h3> NIL. <h3>Disclosure of Interests</h3> None Declared.
AB0248 USEFULNESS OF THE C-REACTIVE PROTEIN TO ALBUMIN RATIO IN ELDERLY PATIENTS WITH RHEUMATOID ARTHRITIS
Authors: M. Ardhaoui, M. Ghali, J. Mahbouba, S. Zrour, I. Bejia, M. Touzi, N. Bergaoui
Journal: Annals of the Rheumatic Diseases (2023)

<h3>Background</h3> C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) are commonly used to assess rheumatoid arthritis (RA) activity. New biomarkers have been developed, such as the CRP to albumin ratio (CAR), which has been proposed as a new inflammatory marker for monitoring disease activity in RA [1]. <h3>Objectives</h3> The aim of our study was to evaluate the relationship between the CAR and RA parameters in a population of elderly patients. <h3>Methods</h3> We conducted a cross-sectional study including patients followed up for RA and aged 65 years or older. CRP, albumin, ESR, orosomucoid and haptoglobin levels were dosed. We calculated the CAR for each patient. <h3>Results</h3> Sixty-three patients (11 men and 52 women) were included. The mean age was 68.17±4.35 years. The median duration of disease progression was 11 years with an IQR of [4-16]. The median CRP was 8.33 mg/L. Mean albumin level was 41.43±4.58 g/L. The median ESR was 47 mm at 1 hour. The mean orosomucoid level was 1.29±0.46 g/L. The mean haptoglobin value was 2.07±0.97 g/L. The mean CAR value was 0.51±0.81 [0.01-3.72]. After statistic analysis, we found a significant association between the CAR and the DAS28 (p=0.03). In addition, CAR was positively correlated with ESR, CRP and Orosomucoid (p&lt;0.001, p=0.01 and p=0.002, respectively). In addition, this ratio was significantly associated with HAQ score (p=0.01), and was higher in patients with major functional impairment (HAQ&gt;2) (p=0.002). However, we did not found significant association between CAR and age, duration of evolution, VAS of pain, seropositivity, structural damage or with the use of corticosteroids. <h3>Conclusion</h3> Our study showed the association of the CAR with DAS28, inflammatory biomarkers and functional impairment among elderly RA patients. This suggests that this ratio could be a reliable tool as a prognostic index to assess disease activity and inflammation in this population. <h3>Reference</h3> [1] Sunar İ, Ataman Ş. Serum C-Reactive Protein/Albumin Ratio in Rheumatoid Arthritis and its Relationship With Disease Activity, Physical Function, and Quality of Life. Arch Rheumatol. 2020 Feb 7;35(2):247-253. <h3>Acknowledgements:</h3> NIL. <h3>Disclosure of Interests</h3> None Declared.
AB0633 PREGNANCY IN SYSTEMIC LUPUS ERYTHEMATOSUS: DESCRIPTION AND COMPARISON OF COMORBIDITIES WITH OTHER SYSTEMIC AUTOIMMUNE DISEASES FROM A RHEUMATOLOGY PREGNANCY CLINIC
Authors: C. Sieiro Santos, B. Magallares, H. Park, H. Marco, E. Llurba, M. Díaz, S. Ros, P. Moya, J. L. Tandaipan, C. Díaz-Torné, C. Pitarch, S. P. Fernandez-Sanchez, A. Laiz, J. Torguet, H. Codes, I. Castellví, H. Corominas
Journal: Annals of the Rheumatic Diseases (2023)

<h3>Background</h3> Pregnancy in patients with systemic lupus erythematosus (SLE) are known to be at high risk for the occurrence of adverse pregnancy outcomes. Pre-conception counselling and risk stratification performed in a multidisciplinary clinical setting with rheumatologists, obstetricians and nephrologists are essential for improving pregnancy outcomes and reducing maternal and perinatal complications in patients with SLE. <h3>Objectives</h3> To describe clinical, obstetric and maternal comorbidities and pregnancy in patients with SLE and patients with other systemic autoimmune diseases (SADs). <h3>Methods</h3> A retrospective cohort study was conducted including patients diagnosed with SLE attending our multidisciplinary pregnancy clinic. Clinical, immunological and obstetric variables were collected. Data related to pregnancy outcomes, delivery and disease activity were also collected. Description of the sample and comparison of groups were carried out. Shapiro-Wilk test was used for variable distribution. <h3>Results</h3> A total of 41 patients attended our outpatient preconception clinic. Comparison and description of the comorbidities, preconception counseling and pregnancy outcomes are summarized in Table 1. A total of 19 (43.2%) patients were diagnosed with SLE. Lupus nephritis was observed in 47% of the patients and 11% had received kidney transplant. Moderate SLEDAI activity (&gt;4) was observed in 44.4%. There were 7 (37%) pregnancies after a mean time of 7.3±6 months since the first visit. SLE patients were significantly older when evaluated at the pregnancy clinic than patients with other SADs. Also, SLE patients exhibited a longer time since the last flare when evaluated at the pregnancy clinic. Significant differences were observed in treatment between both groups: more hydroxychloroquine, synthetic DMARDs and steroids were used in the SLE group. No significant differences in preconception counseling or adverse pregnancy outcomes were observed. <h3>Conclusion</h3> Patients with SLE took longer time since diagnosis and flare to seek pregnancy than patients with other SAD. No differences in pregnancy outcomes or risk profile were observed. <h3>REFERENCES:</h3> NIL. <h3>Acknowledgements:</h3> NIL. <h3>Disclosure of Interests</h3> None Declared.